Guard Therapeutics International AB
Guard Therapeutics International AB (publ), a clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden. Its pipeline products include RMC-035, an intact therapeutic A1M protein, that is in Phase 2b clinical trial for kidney protection with open-heart surgery; in Phase 2a clinical trial for kidney transplantation; and is in preclinical trial to tre… Read more
Guard Therapeutics International AB (GUARD) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -1.630x
Based on the latest financial reports, Guard Therapeutics International AB (GUARD) has a cash flow conversion efficiency ratio of -1.630x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-90.70 Million) by net assets (Skr55.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Guard Therapeutics International AB - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Guard Therapeutics International AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Guard Therapeutics International AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guard Therapeutics International AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Image Systems AB
ST:IS
|
0.046x |
|
Handal Resources Bhd
KLSE:7253
|
0.099x |
|
FIRST SOLAR
BE:F3A
|
-0.007x |
|
YKGI Holdings Bhd
KLSE:7020
|
0.164x |
|
WESTERN DIGITAL
MU:WDC
|
0.003x |
|
Power REIT
NYSE MKT:PW
|
0.077x |
|
Steady Safe TBK PT
JK:SAFE
|
0.359x |
|
Darelle Online Solutions Inc
V:DAR
|
0.002x |
Annual Cash Flow Conversion Efficiency for Guard Therapeutics International AB (2012–2024)
The table below shows the annual cash flow conversion efficiency of Guard Therapeutics International AB from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr37.97 Million | Skr-94.75 Million | -2.496x | -43.52% |
| 2023-12-31 | Skr66.73 Million | Skr-116.05 Million | -1.739x | -201.96% |
| 2022-12-31 | Skr177.36 Million | Skr-102.14 Million | -0.576x | -30.46% |
| 2021-12-31 | Skr175.78 Million | Skr-77.59 Million | -0.441x | +7.34% |
| 2020-12-31 | Skr79.69 Million | Skr-37.96 Million | -0.476x | +58.36% |
| 2019-12-31 | Skr52.62 Million | Skr-60.21 Million | -1.144x | -105.75% |
| 2018-12-31 | Skr-2.94 Million | Skr-58.46 Million | 19.890x | +1063.17% |
| 2017-12-31 | Skr31.96 Million | Skr-66.01 Million | -2.065x | -33.35% |
| 2016-12-31 | Skr30.34 Million | Skr-46.98 Million | -1.549x | -123.61% |
| 2015-12-31 | Skr42.69 Million | Skr-29.56 Million | -0.693x | -427.08% |
| 2014-12-31 | Skr52.25 Million | Skr-6.87 Million | -0.131x | -18.18% |
| 2013-12-31 | Skr25.42 Million | Skr-2.83 Million | -0.111x | -134.81% |
| 2012-12-31 | Skr30.58 Million | Skr-1.45 Million | -0.047x | -- |